Clinical Trials
Study shows benefits of drug on sexual function in men with enlarged prostate
Published in Vaccine Weekly, June 29th, 2005
The study demonstrated that men treated with Uroxatral (alfuzosin HCl), a clinically uroselective alpha-1-blocker for the treatment of the signs and symptoms of enlarged prostate, or benign prostatic hyperplasia (BPH), reported sustained benefit over 2 years in reducing lower urinary tract symptoms (LUTS) and improving sexual function.
Further, a second analysis from the trial demonstrated the relationship between LUTS severity and sexual function and showed that improvement in men with LUTS taking Uroxatral corresponded to similar...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2005-06-29)
More Articles from Vaccine Weekly
- Ovarian Cancer
SCCE is an immunotherapy target for ovarian cancer - Pneumococcal Vaccine
Adult reported pneumococcal vaccination status of children inaccurate - SARS Coronavirus
Researchers suggest an effective immunoprophylaxis strategy in outbreak setting - Syphilis Vaccine
Antibody partially protects against syphilis - Vaccine Delivery
Directed cell migration achieved via chemoattractants from microspheres - Allergy & Immunology
Study shows using controller therapy means fewer ER visits by asthmatic children - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
